Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor
Curation statements for this article:-
Curated by eLife
Evaluation Summary:
This manuscript is of broad interest in light of the COVID-19 pandemic. Characterization of how glycosylation affects interactions between the viral Spike protein and ACE2 receptor can inform efforts to inhibit the SARS-CoV-2. The molecular modeling and functional analysis need to be improved.
(This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. The reviewers remained anonymous to the authors.)
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (eLife)
- Evaluated articles (ScreenIT)
Abstract
Infection and viral entry of SARS-CoV-2 crucially depends on the binding of its Spike protein to angiotensin converting enzyme 2 (ACE2) presented on host cells. Glycosylation of both proteins is critical for this interaction. Recombinant soluble human ACE2 can neutralize SARS-CoV-2 and is currently undergoing clinical tests for the treatment of COVID-19. We used 3D structural models and molecular dynamics simulations to define the ACE2 N-glycans that critically influence Spike-ACE2 complex formation. Engineering of ACE2 N-glycosylation by site-directed mutagenesis or glycosidase treatment resulted in enhanced binding affinities and improved virus neutralization without notable deleterious effects on the structural stability and catalytic activity of the protein. Importantly, simultaneous removal of all accessible N-glycans from recombinant soluble human ACE2 yields a superior SARS-CoV-2 decoy receptor with promise as effective treatment for COVID-19 patients.
Article activity feed
-
-
Evaluation Summary:
This manuscript is of broad interest in light of the COVID-19 pandemic. Characterization of how glycosylation affects interactions between the viral Spike protein and ACE2 receptor can inform efforts to inhibit the SARS-CoV-2. The molecular modeling and functional analysis need to be improved.
(This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. The reviewers remained anonymous to the authors.)
-
Reviewer #1 (Public Review):
Capraz et al extend previous studies of ACE2 protein as an antiviral agent against SARS-CoV-2, which acts by binding to spike. Their work indicates that ACE2 with engineered decreased glycosylation has increased binding (as measured by BLI) and antiviral activity against SARS-CoV-2, without decreasing enzymatic activity of ACE2. Glycosylation of ACE2 is decreased using point mutations and enzymatically.
-
Reviewer #2 (Public Review):
Summary: The authors provide a succinct review of Spike and ACE2 glycosylation and its apparent importance in modulating the interaction of these two proteins. Of particular translational value is the idea that understanding the configurations and effects of ACE2 glycans could inform efforts to develop soluble ACE2 variants as SARS-CoV-2 therapeutics. The authors make a good case for studies to understand the functional roles of glycosylation in this context. For their analysis, the authors begin with 3D modeling of the Spike trimer in complex with one molecule of ACE2. The interaction is mediated by a single RBD (receptor binding domain) in Spike that is modeled in the "up" conformation previously shown to be competent for receptor binding. They then generated a fully glycosylated model and then performed …
Reviewer #2 (Public Review):
Summary: The authors provide a succinct review of Spike and ACE2 glycosylation and its apparent importance in modulating the interaction of these two proteins. Of particular translational value is the idea that understanding the configurations and effects of ACE2 glycans could inform efforts to develop soluble ACE2 variants as SARS-CoV-2 therapeutics. The authors make a good case for studies to understand the functional roles of glycosylation in this context. For their analysis, the authors begin with 3D modeling of the Spike trimer in complex with one molecule of ACE2. The interaction is mediated by a single RBD (receptor binding domain) in Spike that is modeled in the "up" conformation previously shown to be competent for receptor binding. They then generated a fully glycosylated model and then performed molecular dynamics simulation. Post-simulation structural analysis focused primarily on identifying effects of the glycans on the Spike:ACE2 interaction. Two types of apparent effects were concluded: (1) direct interactions between glycans and proteins, and (2) indirect effects. Finally, the authors present functional data on glycan effects on protein stability, binding, and inhibitory activity of soluble ACE2.
Critique: Data and analysis presented in this manuscript generally support the general idea that glycans can have direct and/or modulatory effects on the interaction between the SARS-CoV-2 Spike protein and its receptor ACE2. The molecular dynamics methodology and functional/biophysical experiments themselves appear to have been performed expertly. However, there are deficiencies in the both the experimental design and data analysis, at least some of which can be addressed by more detailed and clearer description of the what was done and how the data were analyzed.
-
SciScore for 10.1101/2021.08.31.458325: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Recombinant expression of all other proteins was performed by transient transfection of HEK293-6E cells, licensed from National Research Council (NRC) of Canada, as previously described. HEK293-6Esuggested: RRID:CVCL_HF20)A German 2019-nCoV isolate (Ref-SKU: 026V-03883, Charité, Berlin, Germany) was propagated in Vero E6 cells. Vero E6suggested: RRID:CVCL_XD71)Recombinant DNA Sentences Resources pCAGGS vector constructs containing either the sequence of the SARS-CoV-2 … SciScore for 10.1101/2021.08.31.458325: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Recombinant expression of all other proteins was performed by transient transfection of HEK293-6E cells, licensed from National Research Council (NRC) of Canada, as previously described. HEK293-6Esuggested: RRID:CVCL_HF20)A German 2019-nCoV isolate (Ref-SKU: 026V-03883, Charité, Berlin, Germany) was propagated in Vero E6 cells. Vero E6suggested: RRID:CVCL_XD71)Recombinant DNA Sentences Resources pCAGGS vector constructs containing either the sequence of the SARS-CoV-2 RBD (residues R319-F541) or the complete luminal domain of Spike, modified in terms of removal of the polybasic furin cleavage site and introduction of two stabilizing point mutations (K986P and V987P), were kindly provided by Florian Krammer pCAGGSsuggested: RRID:Addgene_18926)62,63 Plasmid constructs pcDNA3-sACE2(WT)-Fc(IgG1) and pcDNA3-sACE2-T92Q-Fc(IgG1) were obtained from Addgene (United States). pcDNA3-sACE2suggested: NonepcDNA3-sACE2-T92Q-Fc(IgG1suggested: RRID:Addgene_145170)Software and Algorithms Sentences Resources Protein bands were visualized with the Gel Doc XR+ Imager (Bio-Rad Laboratories). Bio-Rad Laboratoriessuggested: (Bio-Rad Laboratories, RRID:SCR_008426)Fitting was done with Origin 7.0 for DSC software using the non-2-state transition model. Originsuggested: (Origin, RRID:SCR_014212)Statistical analyses were conducted using GraphPad Prism 8. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)5 Molecular models and simulation trajectories are available through the BioExcel COVID-19 Molecular Structure and Therapeutics Hub (https://covid.bioexcel.eu/simulations/). BioExcelsuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04335136 Completed Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) a… Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-